Loading
Latest filing published 15 Jun 2026 for 60 DEGREES PHARMACEUTICALS, INC.. Read the official filing
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Geoffrey S. Dow discloses dealings in 60 Degrees Pharmaceuticals, Inc. to SEC (Form 4). In total, 11 filings cover trades dated from 31 January 2024 to 12 June 2026.
No open-market sale appears; the market trades are 6 purchases worth €44k. The amount is not disclosed for 1 filing. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 2 option exercises. 2026 to date brings 1 purchase and no sales.
The median purchase comes to €7,642. Clusters matter here: 1 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The record was last updated on 15 June 2026 with an open-market purchase in 60 Degrees Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations